Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUX: DM199 in Chronic Kidney Disease
NCT04123613Phase 2Completed
- Sponsor
- DiaMedica Therapeutics
- Start
- Dec 2019
- Primary completion
- Mar 2022
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rinvecalinase alfa in chronic kidney disease (CKD), IgA nephropathy (IgAN) and diabetic kidney disease (DKD) (2 arms), sponsored by DiaMedica Therapeutics. Primary endpoints: Incidence of treatment emergent adverse events at 12 weeks, Change in renal function at 12 weeks and 2 more. Started Dec 2019; status: completed.
02
Drugs
rinvecalinase alfa
03
Conditions
chronic kidney disease (CKD)IgA nephropathy (IgAN)diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT04123613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123613.